GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (FRA:RME) » Definitions » E10

ResMed (FRA:RME) E10 : €3.94 (As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is ResMed E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

ResMed's adjusted earnings per share data for the three months ended in Mar. 2024 was €1.877. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €3.94 for the trailing ten years ended in Mar. 2024.

During the past 12 months, ResMed's average E10 Growth Rate was 12.60% per year. During the past 3 years, the average E10 Growth Rate was 14.90% per year. During the past 5 years, the average E10 Growth Rate was 13.80% per year. During the past 10 years, the average E10 Growth Rate was 13.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of ResMed was 30.10% per year. The lowest was 10.90% per year. And the median was 18.50% per year.

As of today (2024-06-04), ResMed's current stock price is €190.55. ResMed's E10 for the quarter that ended in Mar. 2024 was €3.94. ResMed's Shiller PE Ratio of today is 48.36.

During the past 13 years, the highest Shiller PE Ratio of ResMed was 102.35. The lowest was 33.33. And the median was 48.37.


ResMed E10 Historical Data

The historical data trend for ResMed's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ResMed E10 Chart

ResMed Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.97 2.28 2.42 3.30 3.62

ResMed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.44 3.62 3.84 3.73 3.94

Competitive Comparison of ResMed's E10

For the Medical Instruments & Supplies subindustry, ResMed's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed's Shiller PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ResMed's Shiller PE Ratio falls into.



ResMed E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ResMed's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.877/131.7762*131.7762
=1.877

Current CPI (Mar. 2024) = 131.7762.

ResMed Quarterly Data

per share eps CPI Adj_EPS
201406 0.449 100.560 0.588
201409 0.450 100.428 0.590
201412 0.519 99.070 0.690
201503 0.591 99.621 0.782
201506 0.544 100.684 0.712
201509 0.517 100.392 0.679
201512 0.624 99.792 0.824
201603 0.575 100.470 0.754
201606 0.525 101.688 0.680
201609 0.481 101.861 0.622
201612 0.512 101.863 0.662
201703 0.580 102.862 0.743
201706 0.632 103.349 0.806
201709 0.503 104.136 0.637
201712 0.059 104.011 0.075
201803 0.616 105.290 0.771
201806 0.651 106.317 0.807
201809 0.626 106.507 0.775
201812 0.756 105.998 0.940
201903 0.646 107.251 0.794
201906 0.425 108.070 0.518
201909 0.754 108.329 0.917
201912 0.990 108.420 1.203
202003 1.014 108.902 1.227
202006 1.083 108.767 1.312
202009 1.036 109.815 1.243
202012 1.011 109.897 1.212
202103 -0.454 111.754 -0.535
202106 1.104 114.631 1.269
202109 1.182 115.734 1.346
202112 1.212 117.630 1.358
202203 1.108 121.301 1.204
202206 1.258 125.017 1.326
202209 1.444 125.227 1.520
202212 1.444 125.222 1.520
202303 1.476 127.348 1.527
202306 1.440 128.729 1.474
202309 1.396 129.860 1.417
202312 1.302 129.419 1.326
202403 1.877 131.776 1.877

Add all the adjusted EPS together and divide 10 will get our e10.


ResMed  (FRA:RME) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

ResMed's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=190.55/3.94
=48.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of ResMed was 102.35. The lowest was 33.33. And the median was 48.37.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


ResMed E10 Related Terms

Thank you for viewing the detailed overview of ResMed's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


ResMed (FRA:RME) Business Description

Address
9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

ResMed (FRA:RME) Headlines

No Headlines